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Background: Prostaglandin has been reported to have 
protective effects against liver injury. Use of this agent in 
clinical settings, however, is limited because of drug-
related side effects. This study investigated whether mi-
soprostol, prostaglandin El analogue, and OP-41483, 
prostaglandin 12 analogue, which have fewer adverse ef-
fects with a longer half-life, attenuate ischemic liver 
damage. 
Study Design: Thirty beagle dogs underwent 2 hours of 
hepatic vascular exclusion using venovenous bypass. Mi-
soprostol was administered intravenously for 30 min-
utes before ischemia and for 3 hours after reperfusion. 
o P -41483 was administered intraportally for 30 min-
utes before ischemia (2#Lg/kg/min) and for 3 hours after 
reperfusion (0.5 #Lg/kg/min). Animals were divided into 
five groups: untreated control group (n = 10); high-dose 
misoprostol (total 100 #Lg/kg) group (MP-H, n = 5); 
middle-dose misoprostol (50 #Lg/kg) group (MP-M, 
n = 5); low-dose misoprostol (25 #Lg/kg) group (MP-L, 
n = 5); and OP-41483 group (OP, n = 5). Animal 
survival, hepatic tissue blood flow (HTBF), liver func-
tion, and histology were analyzed. 
Results: Two-week animal survival rates were 30% in 
control, 60% in MP-H, 100% in MP-M, 80% in MP-L, 
and 100% in OP. The treatments with prostaglandin 
analogues improved HTBF, and attenuated liver enzyme 
release, adenine nucleotrides degradation, and histo-
logic abnormalities. In contrast to the MP-H animals 
that exhibited unstable cardiovascular systems, the 
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MP-M, MP-L, and OP animals experienced only tran-
sient hypotension. 
Conclusions: These results indicate that misoprostol 
and 0 P -41483 prevent ischemic liver damage, although 
careful dose adjustment of misoprostol is required to 
obtain the best protection with minimal side effects. (J 
Am ColI Surg 1998;187:276-286. © 1998 by the 
American College of Surgeons) 
Since the protective effects of 16, 16-dimethyl pros-
taglandin E2 on carbon tetrachloride-induced liver 
necrosis were reported by Stachura and colleagues in 
1981,1 many investigators have demonstrated the 
potency of prostaglandins, such as prostaglandin E1 
(PGE1) and prostaglandin 12 (PGI2), against liver 
injury induced by ischemia,2-7 preservation,8.9 and 
various toxinslO,11 in experimental studies. On the 
other hand, since Abecassis and coworkers showed 
the beneficial effects of PGE1 on acute or subacute 
fulminant viral hepatitis in clinical studies for the 
first time in 1987,12 PGE1 has been used clinically in 
cases of liver transplantation, and its potency has 
been reported by some investigators. 13,14 
However, the use of prostaglandin in clinical set-
tings has been limited because of drug-related side 
effects, such as diarrhea, emesis, and hypoten-
sion, 15,16 and its short duration of action. 17,IS Specif-
ically, an unstable blood pressure caused by prosta-
glandin could lead to a critical situation at 
reperfusion after ischemia in liver transplantation. 
Therefore, it is difficult to administer enough pros-
taglandin to exert its effects. Indeed, some clinical 
reports showed that PGE I did not have any benefi-
cial effects on the incidence of primary graft nonfunc-
tion,19 rejection,20 or renal dysfunction20.2 ! in recipi-
ents after liver transplantation. 
Misoprostol, which is a structurally changed an-
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alogue from natural occurring PGEl' enables us to 
overcome these problems. In this compound, typical 
prostaglandin side-effects, such as rhinorrhea, eme-
sis, and diarrhea, are diminished, and undesirable 
actions on the cardiovascular system are also mini-
mized.22 Besides, the active duration of misoprostol, 
whose half life is more than 30 minutes,23 is longer 
than that of natural PGE1• Also, the effects of OP-
41483, a PGI2 analogue, on anti-platelet aggregation 
and vasodilation are half and a tenth as potent as 
natural occurring PGI2, respectively.24 The aim of 
this study is to determine whether these two kinds of 
prostaglandin analogues, misoprostol and OP-
41483, attenuate hepatic warm ischemia and reper-
fusion injury, and to investigate usefulness of these 
drugs in clinical liver transplantation. 
METHODS 
Animals 
Thirty adult female beagle dogs, weighing 8 to 
12 kg, were used for this study. The experiment was 
performed with the approval of the Animal Care and 
Use Committee of the University of Pittsburgh, and 
was managed in accordance with guidelines issued by 
the National Institutes of Health and the Public 
Health Service Policy on the humane use and care of 
laboratory animals. The animals were fasted over-
night but had free access to water before the experi-
ments. After intravenous administration of thiopental-
sodium (25 mg/kg; Abbott Laboratories, North 
Chicago, IL), dogs were intubated and maintained 
with a mixture of oxygen (2 Llmin), nitrous oxide (2 
Llmin) and isoflurane (1.0%) by positive pressure 
mechanical ventilation. The right carotid artery and 
the right jugular vein were cannulated for monitor-
ing of arterial blood pressure and for serial blood 
sampling. An electrolyte solution (Plasmalyte, Bax-
ter, Deerfield, IL) was continuously infused into the 
animals at a rate of 20 mLlkg/h. Electrocardiogram, 
arterial blood gas, electrolytes, and esophageal tem-
perature were monitored throughout the operation. 
Operative procedure 
After midline laparotomy, the liver was com-
pletely skeletonized by dissecting all of the suspen-
sory ligaments and retrohepatic vena cava. Total he-
patic vascular exclusion was initiated by cross-
clamping the portal vein, hepatic artery, and infra-
and supra-hepatic inferior vena cava. Pump-driven 
venovenous bypass (Biomedicus 520D, Minetonka, 
MN) was used to decompress the splanchnic venous 
bed and infrahepatic inferior vena cava.25,26 The by-
pass circuit connected the left femoral vein and 
splenic vein to the left jugular vein. The animals were 
given heparin (50 U/kg) 5 minutes before the initia-
tion of ischemia. At the end of the two-hour ischemic 
period, the clamps were removed, bypass was 
stopped, and a splenectomy was performed. Mter 
ensuring adequate hemostasis, the abdomen was 
rinsed with warm saline and closed. Cefamandole 
(Mandol 1 g; Lilly, Firenze, Italy) was given intraop-
eratively and continued daily for 3 postoperative 
days. Animals were allowed to eat and drink the next 
morning, and followed for 2 weeks postoperatively. 
Experimental groups 
Misoprostol, a PGE1 analogue, and OP-41483, a 
PGI2 analogue, were supplied by Searle (Skokie, IL) 
and Ono Pharmaceutical Co. Ltd. (Osaka, Japan), 
respectively. Misoprostol was administered by con-
tinuous intravenous infusion for 30 minutes before 
ischemia onset (pre) and from 15 minutes before 
reperfusion for 3 hours (post). Animals were divided 
into three groups based on the dosage of misoprostol; 
the high-dose group (MP-H group, n = 5) receiving 
30 JLg/kg (pre) and 70 JLg/kg (post) of misoprostol; 
the middle-dose group (MP-M group, n = 5) receiv-
ing 15 JLg/kg (pre) and 35 JLg/kg (post); and the 
low-dose group (MP-L group, n = 5) receiving 7.5 
JLg/kg (pre) and 17.5 JLg/kg (post). In an OP-41483 
administered group (OP group; n = 5), animals re-
ceived 2 JLg/kg/min OP-41483 for 30 minutes be-
fore ischemia and from 30 minutes before reperfu-
sion 0.5 JLg/kg/min for 3 hours intraportally. 
Animals not receiving any study drugs were used as 
controls (control group, n = 10). 
Determinations 
Two-week animal survival, hepatic tissue blood 
flow (HTBF), liver function tests, tissue biochemis-
try, and histologic assessments were used to evaluate 
the efficacy of the treatment in this study. 
Serial measurements of HTBF were performed 
intraoperatively using a laser Doppler flowmeter 
(Advance Laser Flowmeter, ALF21 , Advance Com-
pany, Ltd., Tokyo, Japan). The probe was placed on 
three lobes of the liver until a stable flow value was 
obtained. To avoid a misreading in HTBF measure-
ments related to respiratory motion, the ventilation 
was always stopped briefly. The mean of three values 
was used as representative value and was expressed as 
a percentage of the value of the preischemic level. 
Peripheral venous blood samples were collected 
serially for determination ofliver enzymes, including 
aspartate aminotransferase (AST) , alanine amino-
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transferase (ALT) and lactate dehydrogenase (LDH), 
by a Technicon RA500 autoanalyzer (Bayer, Tarry-
town, NY). Serum total bile acid (TBA) was mea-
sured by the enzymatic fluorimetric method using 
the Sterongnost-alpha Flu Kit (Nyegaad, Oslo, Nor-
way).27 
Wedge biopsies from the liver were repeated be-
fore ischemia, 1 hour and 2 hours after the onset of 
ischemia, and 15 and 60 minutes after reperfusion. 
The liver tissue was immediately immersed in liquid 
nitrogen. Adenine nucleotides (adenosine triphos-
phate, [ATP]; adenosine diphosphate, [ADP]; and 
adenosine monophosphate, [AMP]), and purine ca-
tabolites (adenosine; inosine; hypoxanthine, [HX]; 
and xanthine, [XA]) were assayed with a high-
performance liquid chromatography system (Waters 
Chromatography Division, Millipore Corp., Mil-
ford, MA; Model 51 0 pumps, Model 484 absorbance 
module, and Model 717 WISP system), equipped 
with a tunable absorbance detector (Water Model 
484).28 The hepatic energy charge (EC), originally 
described by Atkinson 
ATP + ~Aam 
EC = ATP + ADP + AMP 
was calculated.29 
A small portion of each tissue sample taken for 
tissue biochemistry was fixed in buffered formalin, 
paraffin-embedded and stained with hematoxylin-
eosin. The specimens were examined by a single pa-
thologist without knowledge of the groups and the 
timing of tissue sampling. Histologic assessment was 
semiquantitatively performed based on the degree of 
sinusoidal congestion, ischemic hepatocyte injury, 
and hepatocyte necrosis, which was expressed as 
none = 0, mild = 1, moderate = 2, and severe = 3. 
The number of neutrophils that had infiltrated into 
the tissue was counted after Leder's staining,30 and 
expressed as that number per 1,000 hepatocyte 
nuclei. 
Statistical analysis 
The values were expressed as means ± SEM. An-
imal survival was determined using the Fisher's exact 
probability test. The comparison of statistical signif-
icance was performed according to analysis of vari-
ance (ANOYA) analysis for unpaired data; differ-
ences at p < 0.05 were considered to be statistically 
significant. 
RESULTS 
Clinical observation 
Preischemic administration of high dose miso-
prostol triggered severe hypotension and bradycar-
dia, in contrast to the treatments with middle and 
low dose of misoprostal and OP-41483, which 
caused only transient and mild hypotension (Fig. 1). 
These hemodynamics in the MP-H group continued 
even after introduction of liver ischemia; systolic ar-
terial pressure and heart rate remained below 75 and 
70%, respectively, of the initial level during ischemia. 
After reperfusion, blood pressure markedly decreased 
in the control and MP-H groups, while hypotension 
in the MP-M, MP-L, and OP groups was slight. 
Heart rate was stable after reperfusion in the control, 
MP-M, MP-L, and OP groups, but in the MP-H 
group it remained bradycardic even after reperfusion. 
No vasopressor was administered, and atropine was 
used for bradycardia of 50 beat/min or less. 
Neither complications related to bypass, such as 
systemic thrombosis and intestinal congestion, nor 
bleeding tendency caused by misoprostol and OP-
41483 could be found during and after ischemia. 
Immediately after reperfusion, all livers in the 
control group and one out of five livers in the MP-L 
group developed swelling, congestion, and an exten-
sive hypo perfused area, which lasted for 30 to 60 
minutes. The livers in the MP-H group, at first, 
showed fair revascularization without swelling after 
reperfusion, but notable congestion appeared after 
30 minutes. The livers in all MP-M, four MP-L, and 
all OP animals, by contrast, showed smooth revascu-
larization and a remarkably limited hypoperfused 
area. 
After operation, a dry or moist rale was auscu-
lated on the lung field of the MP-H dogs. Postoper-
ative arterial blood gas analysis showed pulmonary 
failure only in the high dose misoprostol adminis-
tered animals (Table 1). At 6 hours after reperfusion, 
pressure of arterial carbon dioxide (PaC02) in the 
MP-H group was significantly higher than that in the 
other four groups. Likewise, pulmonary oxygenation 
was suppressed only in the MP-H group. 
Animal survival 
Survival after surgery is summarized in Fig. 2. 
Two hours of warm liver ischemia was poorly toler-
ated by the untreated control group, in which six 
dogs died within 24 hours, and one on postoperative 
day 10 from liver failure. Two dogs in the MP-H 
group and one dog in the MP-L group died within 
24 hours of reperfusion. In the MP-M and OP 
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Figure 1. Systolic arterial pressure (upper) and heart rate (lower) before, during, and after ischemia (mean ± SEM). 
Values are expressed as a percentage of the level at 30 min bd()re ischemia. *p < 0.05 versus control value. **p < 0.05 
versus control, MP-M, MP-L, and OP values, #p < 0.05 verSllS MP-M, MP-L, and OP values. ##p < 0.05 versus 
control. MP-M, and OP values. MP-H, high-dose misoprostal; MP-M, medium-dose misoprostal; MP-L, low-dose 
misoprostal; ll~ prostaglandin I2 analogue OP-41483. 
groups, each five animals survived more than 14 days 
(p < 0.05 versus control group). 
Hepatic tissue blood flow 
The levels of HTBF after reperfusion were less 
than 25% of initial value in the control group, 
around 50% in the misoprostol-treated groups, and 
around 60% in the OP-41483-treated group (Fig. 
Table 1. Arterial Blood Gas Analysis 6 Hours After 
Reperfusion (Mean ± SEM) 
------~------------
Group 
Control 
MP-H 
MP-M 
MP-L 
OP 
Pa02 (mmHg) PaC02 (mmHg) 
--~------------~----~ 
92.7 ± 3.56 32.1 ± 1.96 
69.2 ± 8.77* 43.6 ± 4.03* 
92.2 ± 3.59 33.6 ± 1.51 
87.1 ± 4.94 33.6 ± 3.19 
94.3 ± 2.20 31.4 ± 1.1 0 
*p < 0.05 versus control, MP-M. MP-L, and OP values, 
Pa02 , pressure of arterial oxygen; PaC0 2 • presure of arterial carbon dioxide, 
MP-H. high-dose misoprostal; MP-M. medium-dose misoprostal; MP-L, low-
dose misoprostal; Or, prostaglandin 12 analogue OP-41483. 
3). There were significant differences between the 
control and study groups in all postischemic 
measurements. 
Liver function test 
Serum AST, ALT and LDH increased sharply 
after reperfusion in all the groups, while the eleva-
tions of liver enzymes in the low dose misoprostol 
group were significantly suppressed during the early 
phase of reperfusion (Fig. 4, Table 2). These values in 
the control and MP-H groups progressively in-
creased and reached peak levels at 12 hours after 
reperfusion. By contrast, treatment with middle and 
low dose misoprostol, and OP-41483 significantly 
inhibited these elevations, although one MP-L ani-
mal that died within 24 hours after surgery showed 
high levels of liver enzymes. 
Serum TBA values increased in all animals after 
reperfusion (Table 2). In the control group, the value 
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Figure 2. Survival of dogs after 2 hours of total hepatic vascular exclusion. *p < 0.05 versus control group. MP-M, 
medium-dose misoprostal; MP-L, low-dose misoprostal; MP-H, high-dose misoprostal. 
progressively increased, while those in the MP-H, 
MP-M, MP-L, and op groups began to decrease 3 
hours after reperfusion. There were significant differ-
ences between the control group and the treated 
groups at 6, 12, and 24 hours after reperfusion. 
Liver tissue biochemistry 
Changes in adenine nucleotides and purine ca-
tabolites in liver tissue at the end of ischemia and 
after reperfusion are summarized in Table 3. Two 
hours of hepatic vascular exclusion in the control 
animals induced a 54.5% decrease in total adenine 
nucleotide (TAN) and an 840% increase in purine 
catabolites, compared with preischemic values. In 
particular, the ischemia caused >90% reduction in 
ATp, and> 1,000% production ofHX and XA. Mi-
soprostol and OP-41483 treatments retarded the 
degradation of adenine nucleotides to purine catabo-
lites during ischemia, especially in the MP-H and OP 
groups. While resynthesis of ATP was suppressed af-
ter reperfusion in control livers, prompt increases in 
ATP levels were seen with treated livers, especially in 
the MP-L and OP groups. Likewise, the levels of 
tissue purine catabolites in the treated livers were 
significantly lower than those in the control livers 
after reperfusion. At 60 minutes after reperfusion, 
however, ATP levels in the MP-H livers were not 
different from those in control livers. Concerning 
changes in hepatic energy charge (EC), no significant 
differences were found among all the groups. 
Histopathology 
Histopathologic examination showed no differ-
ences between control and misoprostol-treated 
groups at the end of ischemia. After reperfusion, the 
control livers developed sinusoidal congestion and 
derangement, ballooning, bridging hepatocyte ne-
crosis, and endothelial cell detachment. According to 
the histologic score, it was demonstrated that treat-
ment with middle and low dose misoprostol, and 
OP-41483 significantly alleviated these structural 
abnormalities (Table 4). The high dose-treated liver 
showed almost the same sinusoidal congestion and 
parenchymal injury as those of the control group, 
even though parenchymal necrosis was rarely seen in 
the MP-H livers. The numbers of neutrophils infil-
trated into postischemic livers 60 minutes after 
reperfusion in the MP-H and OP groups were signif-
icantly less than that in control group. (Table 4). 
DISCUSSION 
In this study, we demonstrated that two kinds of 
prostaglandin analogues, misoprostol and OP-
41483, lessened microcirculatory disturbance, atten-
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Figure 3. Tissue blood flow in the liver before, during, and after ischemia (means:!: SEM). Values are expressed as a 
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uated liver injury, and improved animal survival after 
reperfusion following 2 hours of hepatic warm isch-
emia. In addition, these prostaglandins inhibited ad-
enine nucleotide degradation in ischemic tissues, en-
hanced ATP resynthesis, and improved histopathologic 
findings. 
Prostaglandins, including PGEl and PGlz, are 
said to have a wide range of effects against liver injury 
by ischemia and reperfusion. This potency is based 
on the ability of prostaglandin to activate adenylate 
cyclase.31 ,32 Intracellular cyclic adenosine 3', 5' 
monophosphate (cyclic AMP), which is increased by 
adenylate cyclase, acts as a second messenger of pros-
taglandin on hepatocytes, vascular smooth muscles, 
platelets, and neutrophils. 
In hepatocytes, cyclic AMP is well known to pro-
duce an efflux of calcium.33 This effect leads to an 
attenuation of hepatocyte injury during and after 
liver ischemia. Liver ischemia causes the progressive 
degradation of adenine nucleotides, resulting in the 
production of purine catabolites.34 Harvey and asso-
ciates demonstrated that hepatocyte injury began 
during ischemia.35 Their study showed that the level 
of tissue malondialdehyde as well as hypoxanthine 
and xanthine significantly increased 2 hours after he-
patic warm preservation. This result indicates that 
some lipid peroxidation by the xanthine oxidase sys-
tem,36 which causes direct cellular injury, occurred 
not only after but also before reperfusion. Likewise, 
depletion of the tissue stores of ATP results in an 
accumulation of intracellular calcium. This accumu-
lating calcium activates calcium-dependent ATP-ase, 
leading to a further depletion of tissue stores of 
ATp'37 Intracellular accumulated calcium activates 
proteolytic enzyme systems, which causes additional 
hepatocellular injury at the same time as that caused 
by lipid peroxidation from the xanthine oxidase sys-
tem.38 Cyclic AMp, which produces an efflux of cal-
cium accumulated intracellularly by ischemia and 
ATP depletion, prevents the intracellular buildup of 
282 Totsuka et a1 Attenuation ofIschemic Liver Injury J Am Coli Surg 
Figure 4. Changes in serum aspartate aminotransferase (AST) levels after ischemia (means ± SEM). *p < 0.05 versus 
control value, #p < 0.05 versus control and MP-H values. MP-H, high-dose misoprostal; MP-M, medium-dose 
misoprostal; MP-L, low-dose misoprostal; Or, prostaglandin 12 analogue OP-41483. 
Table 2. Alanine Aminotransferase, Lactate Dehydrogenase, and Total Bile Acid Levels after Ischemia (Mean ± SEM) 
Preischemia 60 minutes 3 hours 6 hours 12 hours 24 hours 
~-----
--- ----
Alanine aminotransferase 
(U/L) 
Control 32.2±4.2 4,961±798 6,576± 1,007 9,332± 1,128 13,563± 1,379 12,681 ± 1,451 
MP-H 26.2±4.0 3,527±686 4,057±736 6,248±696* 9,006± 1,629* 4,414±448* 
MP-M 26.6±5.5 2,302±1,183* 2,745±1,300* 1,644±465t 1,668±655t 1,315±361 1 
MP-L 23.0±2.8 1,444±508* 2,087±749* 2,580±842t 2,544± 1,005t 2,185±1,028t 
OP 18.2±3.0 2,274±540* 2,873±5lO* 2,082±3331 1,443±272t 723±241 t 
Lactate dehydrogenase 
(U/L) 
Control 80.6±15.7 3,385±474 3,128±179 2,906±559 3,046±634 1,441 ±216 
MP-H 40.6±6.3 2,966±480 2,784±291 2,662±505 2,919±532 1,099±491 
MP-M 35.2±8.8 1,199±541 t 934±358"1 521±153t 358±77.8t 195±53.3t 
MP-L 42.0±4.9 1,364±527t 1,165±419t 1,290±401* 813±228t 415± 173 t 
OP 36.4±4.6 1,207±4581 1,109±404t 354±9l.9t 244±36.5t 190±52.1t 
Total bile acid 
(f.LmollL) 
Control 0.3±0.3 48.5±12.4 100.2± 11.6 133.8± 12.5 124.3± 14.0 175.4±42.2 
MP-H 0 66.0±17.6 90.0± 14.2 8l.9±22.5* 50.8±35.5* 11.9± 14.5* 
MP-M 0 13.7±6.3 18.0±8.5t 10.2±lO.Ot 0.74±0.83t 0* 
MP-L 0 16.3± 11.2 43.9±23.4* 43.9±26.9* 14.6±8.5* 5.4±3.7* 
OP 0 32.9±30.6 66.2±61.5 45.5±27.0* 23.6±9.1* 16.0± 18.2* 
*p < 0.05 versus control value. 
t p < 0.05 versus control and MP-H values. 
MP-H, high-dose misoprostal; MP-M, medium-dose misoprostal; MP-L, low-dose misoprostal; OP, prostaglandin I2 analogue 01'-41483. 
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Table 3. Tissue Concentrations of Adenine Nucleotides and Purine Catabolites (Nmol/g tissue) During and after 
Ischemia (Mean ± SEM) 
Group EC TAN ATP ADP AMP HX XA 
Normal 0.82±0.02 3,774±314.1 2,666±311.6 
The end of 
il94.0± 121.9 213.6±29.0 102.7±2l.6 4.20±2.94 
ischemia 
Control 0.23±0.03 1,719±147.8 236.9±45.2 335.0±32.5 1,147± 107.2 460.0±29.7 659.0±54.3 
MP-H 0.26±0.05 2,650±285.0* 406.3±120.1 594.3±76.1* 1,649±249.1 * 223.8±58.7* 359.2±88.8* 
MP-M 0.28±0.03 2,305±127.1 379.3±49.0 498.6±43.3 1426.5± 132.7 254.2±37.2* 491.3±48.9 
MP-L 0.30±0.03 2,306±347.2 413.5± 115.0 619.8±12l.5* 1,272± 118.6 183.4±41.1* 362.4± 85.2* 
OP 0.29±0.O3 2,400±273.5* 405.7±44.2 566.4±56.9* 1,428±230.9 218.0±38.1 * 394.6± 58.8* 
15 minutes after 
reperfusion 
Control 0.72±0.04 1,417±234.0 846.8±170.2 410.0±73.3 160.0±17.8 13l.6±25.5 24.0±9.3 
MP-H 0.66±0.02 2553±337.7* 1,347± 110.2 629.7± 132.0 576.2± 136.0* 38.5±5.9* 6.18±7.14* 
MP-M 0.65±0.05 2,446±203.5* 1,314±255.4 585.5±52.9 546.4±72.9* 32.9±4.0* l.49±0.81 * 
MP-L 0.75±0.04 2,884±338.6* 1,909±335.2* 597.2±77.1 378.4±47.5* 36.6±3.7* 0.78±0.55* 
OP 0.69±0.05 2,738± 193.7* 1,597±205.9* 607.6± 123.7 533.9± 103.1 * 34.8±4.0* l.30±0.92* 
60 minutes after 
reperfusion 
Control 0.83±0.02 1,669±160.1 1,227±138.3 329.4±37.4 112.2±14.7 105.5±20.5 44.3±9.9 
MP-H 0.69±0.04 2,146±307.5 1,225 ± 282.3 574.9±81.7* 345.9±58.9 33.7±7.6* 23.5±21.8 
MP-M 0.77±0.04 2,748±276.2* 1,895±304.7 524.4± 16.3* 328.9±41.3 29.5±2.0* O' 
MP-L 0.78±O.03 2,535 ±294.5* 1,762±250.2 467.9±67.6 305.4±44.9 25.6± 1.1 * 0* 
OP 0.77±0.10 2,968± 163.7t 1,999 ± 369.2 t 547.9±1l5.7* 42l.0±240.1* 37.2±5.1* 1.03± 1.15* 
'p < 0.05 versus control value; tp < 0.05 verSllS control and MI'-H values. 
ADP, adenosine diphosphate; AMP, adenosine monophosphate; Aqf~ adenosine triphosphate; Ee, energy charge; HX, hypoxanthine; MP-H, high-dose miso-
prostal; MP-L, low-dose misoprostal; MP-M, medium-dose misoprostal; Or, proS{aglandin 12 analogue 01'-41483; TAN, total adenine nucleotide; XA, xanthine. 
calcium and consumption of ATp, resulting in the 
stabilization of the hepatocellular membrane, and in 
an intracellular adenine nucleotide preservation that 
prevents activation of the xanthine oxidase system. In 
the present study, degradation of adenine nucleotides 
and elevation of purine cat abo lites after two hours of 
ischemia were retarded by misoprostol and op-
41483 treatments. These results suggest that these 
prostaglandin analogues attenuated liver injury dur-
ing ischemia and immediately after reperfusion. 
After reperfusion, hepatic tissue blood flow was 
markedly improved in the misoprostol and op-
41483 treated groups. This observation agrees with 
previous reports; an improvement was made in the 
hepatic microcirculatory system by vasodilatory ef-
fect and anti platelet action of prostaglandin after 
Table 4. Microscopic Grading of Histologic Changes and Neutrophil Counts (Neutrophils/l,OOO hepatocytes) 
(Mean ± SEM) 
Group Sinusoidal congestion 
Normal 
15 minutes after reperfusion 
Control 
MP-H 
MP-M 
MP-L 
OP 
60 minutes after reperfusion 
Control 
MP-H 
MP-M 
MP-L 
OP 
*p < 0.05 versus control value. 
tp < 0.05 versus MP-H value. 
"p < 0.05 versus control and MP-H values. 
§p < 0.05 versus control and MP-H values. 
0 
1.47 ± 0.22 
1.80 ± 0.22 
1.20 ± 0.22 
0.80 ± O.22T 
1.00 ± a 
1.93±0.19 
2.40 ± 0.27 
1.00 ± 0.20t 
l.80 ± O.22t 
1.20 ± 0.20+ 
Hepatocytes injury Hepatocytes necrosis Neutrophils count 
----
---------
0 0 16.7 ± 2.4 
1.07 ± 0.12 0.07 ± 0.07 39.4 ± 13.1 
0.80 ± 0.22 0 22.4 ± 8.2 
0.60 ± 0.27 0 35.3 ± 6.7 
1.60 ± 0.27 0.60 ± 0.27 29.3 ± 8.4 
1.00 ± 0 0 24.0 ± 5.6 
1.87 ± 0.17 1.13±0.17 57.2 ± 19.1 
1.60 ± 0.27 0.20 ± 0.22* 3l.0 ± 9.6§ 
0.60 ± 0.27+ 0* 73.7 ± 6.9 
1.00 ± 0.35* 0* 39.0 ± 8.8 
0.60 ± 0.40+ 0* 35.6 ± 1O.5§ 
MP-H, high-dose misoprostal; MP-L, low-dose misoprostal; MP-M, medium-dose misoprostal; Or, prostaglandin 12 analogue 01'-41483. 
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reperfusion.3 '),40 Cyclic AMP was reported to pro-
duce an efflux of calcium in vascular smooth muscles 
through the activation of the Ca + + -activated K+ 
channel. 41 The decline of in tracellular calci urn causes 
vasodilation as a consequence of vasorelaxation. 
In platelets, cyclic AMP suppresses the inositol 
phospholipid metabolic turnover that generates both 
inositol I,4,5-triphosphate (IP 3) and I,2-diacyl-
glycerol (DAG).42,41 This function prevents the mo-
bilization of intracellular calcium by IP 3 and the ac-
tivation of protein kinase C by DAG. In this 
mechanism, cyclic AMP inhibits the process of plate-
let aggregation, such as ADP release and activation of 
phospholipase A2 , which produces thromboxan A2 
from arachidonic acid. These functions produced by 
prostaglandin contribute to an increase in organ 
blood flow. 
Many investigators demonstrated that prosta-
glandin has antiinflammatory potency. At the initial 
phase of reperfusion after liver ischemia, activated 
Kupffer cells release the inflammatory mediators 
such as tumor necrosis factor or interleukin-I.44 
Neutrophils, which are activated by these mediators 
or activated endothelial cells,45 infiltrate the liver tis-
sue and produce reactive oxygen species by means of 
the NADPH oxidase system, resulting in the progres-
sion of the liver injury.46 This injury urges platelets 
into an activation, causing aggregation and further 
activationY As a result, microcirculatory failure of 
the liver has occurred throughout these processes. 
On the other hand, cyclic AMp, which is increased by 
prostaglandin in neutrophils, inhibits intracellular 
calcium elevation and activation of protein kinase C, 
resulting in direct suppression of neutrophil adhe-
sion, lysosomal enzyme release, and NADPH oxidase 
system.48 Since prostaglandin E2 was reported to in-
hibit the release of inflammatory mediators from ac-
tivated Kupffer cells by elevating intracellular cyclic 
AMp,49 prostaglandin may block the activation of 
neutrophils induced by the mediators indirectly. In 
this study, high doses of misoprostol and OP-41483 
significantly inhibited the infiltration of neutrophils 
60 minutes after reperfusion. Although the numbers 
of neutrophils in the MP-M and MP-L livers were 
not different from those in control livers, the eleva-
tion ofliver enzyme release was markedly suppressed 
in both the MP-M and MP-L groups as well as in the 
OP group compared with the control group for 3 
hours after reperfusion. The values of TBA, which 
reflect hepatic circulation and hepatocyte function 
more sensitively than the standard liver function 
tests, 50 were sustained at low levels in these three 
groups. These results suggest that the misoprostol 
and OP-41483 treatments could protect the liver 
from progressive damage by neutrophils after 
reperfusion. 
In this study, we made three misoprostol-treated 
groups depending on the drug dosage, because the 
potency and optimal dose of misoprostol against liver 
injury has not yet been determined. Dosages of mi-
soprostolused were based on a previous report. Using 
a model of 90 minutes partial liver ischemia in rats, 
Lim and associates51 showed that both two-dose 
treatments of 25 mg/kg misoprostal before ischemia 
and before reperfusion, and a single dose treatment 
of 25 mg/kg misoprostol before ischemia were effec-
tive in attenuating ischemia and reperfusion injury. 
We tried three dosages: total IOO, 50, and 25 mg/kg 
misoprostol, and we divided the drug administration 
between before and after hepatic ischemia in the ratio 
of seven to three. To avoid sudden changes in cardio-
vascular system caused by a bolus injection, the drug 
was administered by continuous intravenous infu-
sion. We found that the high dose misoprostol treat-
ment partially protected the liver against ischemic 
injury, but produced an unstable cardiovascular sys-
tem and pulmonary dysfunction that would have an 
adverse influence on liver function. We considered 
that this adverse effect was due to not only vasodila-
tion but also vagal reflexes caused by high-dose mi-
soprostol administration. Previously, two clinical 
cases were reported in which cardiac arrest occurred 
after severe hypotension and bradycardia induced by 
E-type prostaglandin treatment. 52, 51 In experimental 
study, it was demonstrated that PGI2 stimulated va-
gal cardiac c fibers, causing vagal reflexes, such as a 
decrease in cardiac output and bradycardia. 54,55 
Therefore, an excessive dose of misoprostol as well as 
PGI2 may produce the vagal reflex, although this 
hypothesis has not been proved. In the present study, 
severe hypotension and bradycardia were exhibited 
in the MP-H animals, and this cardiovascular insta-
bility must have an adverse influence on the post-
ischemic condition. In this group, sinusoidal conges-
tion and hepatocyte injury developed, probably from 
low cardiac function after reperfusion, resulting in 
suppression of ATP resynthesis, even though the in-
hibition of adenine nucleotide degradation during 
ischemia and the improvement ofHTBF after reper-
fusion were induced by treatment with high dose 
misoprostol. In addition to the liver findings, the 
high dose misoprostol treatment led to pulmonary 
failure after the operation. Although histologic ex-
amination of the lung was not performed, we conjec-
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tured that pulmonary edema occurred in the MP-H 
animals by misoprostol-induced heart failure and di-
latation of the pulmonary artery. 
Regarding two lower dose misoprostol groups, 
2-week animal survival and amelioration of histo-
logic abnormalities in the MP-L group were poorer 
than those in the MP-M group, although inhibitions 
of liver enzyme release and bile acid elevation were 
significant in both groups. This result suggests that 
the low dose misoprostol treatment had a less desir-
able effect than the middle dose treatment. 
On the other hand, the dose of OP-41483 was 
based on our previous study. 56 When PGI2 was ad-
ministered at a rate of 1 or 2 /Lg/kg/min for 60 min-
utes via the portal vein before 3 hours warm ischemia 
of the canine liver, 2 /Lg/kg/min-PGI2 treatment sig-
nificantly improved the survival rate and remarkably 
suppressed the serum liver enzyme elevation, and 1 
/Lg/kg/min-PGI2 showed low effects. In addition to 
the OP-41483 administration at a rate of2/Lg/g/min 
for 30 minutes before ischemia, 3 hours infusion of 
0.5 /Lg/kg/min OP-41483 from 30 minutes before 
reperfusion was performed in the present study, be-
cause it was considered that the halflife ofOP-41483 
is too short to inhibit the actions of platelets and 
neutrophils after reperfusion. OP-41483 was infused 
via the portal vein to alleviate the cardiovascular side 
effects of this drug, because PGI2 including OP-
41483 is not metabolized by the lung but by the 
liver. 57 In this method of administration, OP-41483 
exerted its effects on our hepatic ischemia and reper-
fusion model with minimal side effects. 
In conclusion, treatments with misoprostol, a 
PGE1 analogue, and with OP-41483, a PGI2 ana-
logue, successfully prevented liver damage after 
2-hour warm ischemia. Attenuation of adenine nu-
cleotide degradation during ischemia, improvement 
of liver microcirculation at the early phase of reper-
fusion, and inhibition of neutrophil activation 
played an important role in liver protection by these 
prostaglandin analogues. These prostaglandin ana-
logues should be positive applications to clinical liver 
transplantation. 
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